NEWSLETTER VOL. 6 AGT’s progress over the first half of 2018 has been tremendous: six patents granted, major advances in all of its key projects: HIV, PKU and immuno-oncology, substantial momentum on socia...
American Gene Technologies International Inc. (AGT)
A private biotechnology company developing cures and treatments
for Infectious diseases, cancers and monogenic disorders.
AGT, has a broad, robust lentiviral delivery platform evolved over ten years of advanced development. AGT has an extensive and growing patent portfolio surrounding its lentiviral platform innovations that accelerate the development of a wide variety of drug candidates. This platform allows AGT to pursue exciting clinical “cures” in large and orphan indications and complex diseases. AGT’s proprietary platform technologies provide reusable components that allow AGT and its internationally recognized collaborators to create new drugs in a fraction of the time of traditional drug development processes and other drug companies. AGT will begin clinical trials this year for an HIV functional cure based on a successful pre-IND meeting with FDA in October of 2016.
Contact Neil Lyons
If you are interested in learning about the company and investment opportunities please contact our head of finance, Neil Lyons for more information.
Latest AGT Tweets
ICYMI - These Five Capital Region Biotech's Are The Fastest Growing in America, Find out who The Next Generation of Gene Therapy Companies are, and more news from the #BioHealthCapitalRegion @GSKUS @RoosterBio @officialatcc @MDTEDCO https://t.co/9N0KaxfBet https://t.co/WSjJgegNl7